Importantly, as shown in prostate cancer (21), a combination of EGF and androgen further induced AR transcriptional activity in all the three bladder cancer lines tested and the AR antagonist HF completely abolished AR transactivation induced by EGF, androgen, or both at least in UMUC3. Here, AR is linked to urinary bladder carcinoma.